Cancer progression is aided by the ability of tumors to evade recognition by the immune system. In this issue of the Journal of Clinical Investigation, Gerard Blobe and colleagues at Duke University identify a mechanism by which tumors evade detection. Using mouse models of breast cancer and melanoma, they show that loss of the Type III TGF-β receptor (TGFBR3) in tumors promotes cancer progression by altering signaling in tumor-associated immune cells.
This study supports the use of TGF-β inhibitors to enhance the efficacy of therapies that promote immune-mediated elimination of tumor cells.
TITLE: Type III TGF-β receptor downregulation generates and immunotolerant tumor microenvironment
AUTHOR CONTACT: Gerard C. Blobe
Duke University, Durham, NC, USA
Phone: (919) 668-1352; Fax: (919) 681-6906; E-mail: blobe001@mc.duke.edu
View this article at: http://www.jci.org/articles/view/65745?key=f673123b974c4089ed3b
Journal
Journal of Clinical Investigation